Treatment with oral infigratinib for 52 weeks in PROPEL 3 resulted in favorable trends against placebo in clinically meaningful exploratory endpoints including sleep apnea and otitis media events ...
The PROPEL 3 study showed oral infigratinib improved growth, reduced sleep apnea, and lowered ear infection rates in children ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results